Brensocatib (formerly known as AZD-7986; INS-1007) is a novel, second generation, highly potent, covalent reversible, and selective DPP1 (Dipeptidyl peptidase 1) inhibitor with anti-COPD effects.

DBPR108 is a novel, potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; It shows no inhibition on DDP8 and DPP9.

UAMC00039 dihydrochloride is a novel, potent, reversible and competitive dipeptidyl peptidase II (DPP-II) inhibitor with an IC50 of 0.48 nM.

Teneligliptin (MP513; trade name Tenelia in Japan) is a novel, potent, orally bioavailable and long-lasting dipeptidyl peptidase-4 (DPP-4) inhibitor; it competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.

Teneligliptin HBr hydrate (formerly MP513; MP-513; trade name Tenelia in Japan), the hydrobromide salt and hydrated form of Teneligliptin, is an orally bioavailable and long-lasting dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes mellitus in Japan.

Sitagliptin phosphate (MK431; Januvia), the phosphate salt of Sitagliptin, is an antihyperglycemic agent (sugar-lowering) and antidiabetic medication that act as a potent inhibitor of DPP-IV (dipeptidyl peptidase-4) with IC50 of 19 nM in Caco-2 cell extracts.